Compare Crispr Therapeutics AG (CRSP) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares MSCI Hong Kong ETF — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while iShares MSCI Hong Kong ETF trades at $21.82. The key difference: iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | EWH | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $24.55 |
52-Week Low | $44.34 | $20.09 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
EWH trades at $21.30, down 0.93% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock faces resistance at $22 with support at $21. Recent news highlights Hong Kong's growing prominence as a wealth hub and market volatility in Asian indexes. Key financial ratios remain unavailable in current data.
The outlook remains cautious with technical resistance limiting near-term upside. Hong Kong's economic developments provide potential catalysts, but lack of fundamental data and mixed technical indicators suggest careful monitoring of earnings and market sentiment is essential for investment decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
